US Pharma MarketingThe post Satellos’ oral DMD drug improves arm movement after six months in Phase II appeared first on Clinical Trials Arena.
Satellos’ oral DMD drug improves arm movement after six months in Phase II
In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial. In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial. The DMD market is set to be worth $5.2bn in 2033, according to GlobalData analysis. Credit: Kateryna Kon / Shutterstock.com Satellos Bioscience’s oral Duchenne muscular dystrophy (DMD) drug has increased upper limb activity in four patients in a Phase II trial. In the TRAILHEAD study (NCT06867107), an open-label long-term follow-up study for those who participated in the Phase Ia/b CL-101…
In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial.
Source: Clinical Trials Arena